Adoptive Transfer of Anti-Nucleolin T Cells Combined with PD-L1 Inhibition against Triple-Negative Breast Cancer | Citedby Results | Molecular Cancer Therapeutics | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

Adoptive Transfer of Anti-Nucleolin T Cells Combined with PD-L1 Inhibition against Triple-Negative Breast Cancer

Mol Cancer Ther (2022) 21 (5): 727–739.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Development of hybrid aptamers-engineered PROTACs for degrading VEGF165 in both tumor- and vascular endothelial cells

Ziting Feng
Duoli Xie
Fang Qiu
Jie Huang
Zhuqian Wang
Chao Liang

European Journal of Medicinal Chemistry (2025) 281: 117027.

Mesothelin- and nucleolin-specific T cells from combined short peptides effectively kill triple-negative breast cancer cells

Suyanee Thongchot
Krittaya Aksonnam
Jaturawitt Prasopsiri
Malee Warnnissorn
Doonyapat Sa-nguanraksa
Pornchai O-Charoenrat
Peti Thuwajit
Pa-thai Yenchitsomanus
Chanitra Thuwajit

BMC Medicine (2024) 22 (1)

Novel combination therapy using recombinant oncolytic adenovirus silk hydrogel and PD-L1 inhibitor for bladder cancer treatment

Wenqiang Zhang
Jianqiang Zhang
Jingwei Zhang
Jing Chu
Zhenxing Zhang

Journal of Nanobiotechnology (2024) 22 (1)

Design of Murine Double Minute 2 Proteolysis Targeting Chimera Degraders with a Built-In Tumor-Targeting Ability

Zhuqian Wang
Siran Yue
Xinxin Chen
Jin Li
Peixi Zhu
Hongzhen Chen
Fang Qiu
Duoli Xie
Yiying Liang
Defang Li
Aiping Lu
Chao Liang

Journal of Medicinal Chemistry (2024) 67 (21): 18865.

Granulocyte-Macrophage Colony-Stimulating Factor in Combination With Chemoradiation for Recurrent or Metastatic Cervical Cancer

Na Zhang
Ming-Fang Guo

Cureus (2024)

Stimuli‐Responsive Aptamer‐Drug Conjugates for Targeted Drug Delivery and Controlled Drug Release

Shanshan Zhu
Huan Gao
Wenyuan Li
Xiaocong He
Panpan Jiang
Feng Xu
Guorui Jin
Hui Guo

Advanced Healthcare Materials (2024)

Advancing targeted combination chemotherapy in triple negative breast cancer: nucleolin aptamer-mediated controlled drug release

Yuan Ma
Duoli Xie
Zefeng Chen
Xinyang Shen
Xiaoqiu Wu
Feng Ding
Shijian Ding
Yufei Pan
Fangfei Li
Aiping Lu
Ge Zhang

Journal of Translational Medicine (2024) 22 (1)

Nucleolin‑based targeting strategies in cancer treatment: Focus on cancer immunotherapy (Review)

Suyanee Thongchot
Krittaya Aksonnam
Peti Thuwajit
Pa-Thai Yenchitsomanus
Chanitra Thuwajit

International Journal of Molecular Medicine (2023) 52 (3)

Recent advances in microfluidic-based cancer immunotherapy-on-a-chip strategies

Thi Kim Ngan Ngo
Cheng-Hsiang Kuo
Ting-Yuan Tu

Biomicrofluidics (2023) 17 (1)

WT1 Pulsed Human CD141+ Dendritic Cell Vaccine Has High Potential in Solid Tumor-Targeted Immunotherapy

Sung Yoon Cho
Seong Mun Jeong
Young Joo Jeon
Sun Ja Yang
Ju Eun Hwang
Byung Moo Yoo
Hyun Soo Kim

International Journal of Molecular Sciences (2023) 24 (2): 1501.

Anti-PD-L1 × anti-CD3 bispecific T-cell engager-armed T cells can overcome immunosuppression and redirect T cells to kill breast cancer cells expressing PD-L1

Piriya Luangwattananun
Thanich Sangsuwannukul
Kamonlapat Supimon
Chanitra Thuwajit
Thaweesak Chieochansin
Doonyapat Sa-nguanraksa
Norasate Samarnthai
Pornchai O-Charoenrat
Mutita Junking
Pa-thai Yenchitsomanus

International Immunopharmacology (2023) 124: 111012.

Facts and prospects of peptide in targeted therapy and immune regulation against triple-negative breast cancer

Yongxiu Huang
Anqi Zeng
Linjiang Song

Frontiers in Immunology (2023) 14

Cellular localization of nucleolin determines the prognosis in cancers: a meta-analysis

Supaporn Yangngam
Jaturawitt Prasopsiri
Phimmada Hatthakarnkul
Suyanee Thongchot
Peti Thuwajit
Pa-thai Yenchitsomanus
Joanne Edwards
Chanitra Thuwajit

Journal of Molecular Medicine (2022) 100 (8): 1145.